Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Trevi Therapeutics Inc (TRVI)

195 + Investors. Track Smart Money conviction in TRVI. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +15
Streak
7Q ▲
Buyers last Q
55%

Smart Money Signals — TRVI

Based on 196 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added TRVI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
196 hedge funds hold TRVI right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +40% more funds vs a year ago

fund count last 6Q
+56 new funds entered over the past year (+40% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 55% buying

108 buying90 selling
Last quarter: 108 funds bought or added vs 90 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+8 vs last Q)

new funds entering per quarter
Funds opening a new TRVI position: 38 → 34 → 33 → 41. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 30% long-term, 36% new

■ 30% conviction (2yr+) ■ 34% medium ■ 36% new
Of the 196 current holders: 59 (30%) held >2 years, 66 held 1–2 years, and 71 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
➡️

Steady discovery — ~41 new funds/quarter

47 → 38 → 34 → 33 → 41 new funds/Q
New funds entering each quarter: 38 → 34 → 33 → 41. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 33% veterans, 51% new entrants

■ 33% veterans ■ 16% 1-2yr ■ 51% new
Of 202 current holders: 67 (33%) held 2+ years, 32 held 1–2 years, 103 (51%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds
41 of 194 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TRVI

In 2026 Q1, 108 hedge funds were net buyers of TRVI (41 opened a new position, 67 added to an existing one), while 90 reduced or exited (64 trimmed, 26 sold completely) — a 55% buyer ratio, indicating a slight buying edge. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 23% of total institutional value in TRVI is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +15 funds (more new holders than closures). Total institutional holders: 196.

Hedge Fund Ownership: TRVI

How many hedge funds hold TRVI — quarterly history vs. share price
Quarterly hedge fund ownership of TRVI vs. share price

Market Analysis: TRVI

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TRVI

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Trevi Therapeutics Inc (TRVI) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TRVI has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
TRVI
nan%
XLV
+2.1%

TRVI outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
TRVI
nan%
XLV
+3.2%

Since the filing became public, TRVI outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

20 top-rated funds 6 high-conviction
Consensus
5.7
/ 10
breadth
×
Elite
4.3
/ 10
conviction
Hedge Fund Positioning: TRVI
195 + Investors

Track Smart Money conviction in TRVI. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 195 181 7.73%
13F Shares 136M 131M 3.83%
Total Value $1.63B $1.64B -0.76%
New Positions 40 33 +7
Increased Positions 64 73 -9
Closed Positions 26 16 +10
Reduced Positions 62 50 +12
Total Calls 5 6 -16.67%
Total Puts 3 3 -
PUT/CALL Ratio 0.6 0.5 Bullish

Statistics: TRVI

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

195 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TRVI. Verified SEC 13F-HR filings.

QUARTER:
Top 25 TRVI holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 NEA Management Company, LLC 8.97% 13,222,228 $157.7M
2 Acorn Capital Advisors, LLC 7.27% 2,144,844 $25.6M
3 Pivotal bioVenture Partners Investment Advisor LLC 6.63% 1,553,726 $18.5M
4 Vivo Capital, LLC 5.07% 5,094,668 $60.8M
5 Artia Global Partners LP 4.81% 2,013,602 $24.0M
6 KVP Capital Advisors, LP 3.69% 414,000 $4.9M
7 Frazier Life Sciences Management, L.P. 3.05% 9,939,547 $118.6M
8 MPM BioImpact LLC 3.04% 3,298,430 $39.4M
9 Superstring Capital Management LP 2.14% 251,566 $3.0M
10 Octagon Capital Advisors LP 1.96% 1,485,000 $17.7M
11 Propel Bio Management, LLC 1.67% 223,802 $2.6M
12 NAN FUNG TRINITY (HK) Ltd 1.50% 1,142,950 $13.6M
13 Logos Global Management LP 1.43% 2,400,000 $28.6M
14 Affinity Asset Advisors, LLC 1.23% 2,000,172 $23.9M
15 Sphera Funds Management LTD. 1.09% 574,029 $6.8M
16 Jones Hill Capital LP 0.95% 370,175 $4.4M
17 Soleus Capital Management, L.P. 0.78% 1,620,000 $19.3M
18 Sectoral Asset Management Inc 0.78% 74,446 $939K
19 Emerald Mutual Fund Advisers Trust 0.73% 1,262,492 $15.1M
20 Vestal Point Capital, LP 0.72% 2,166,504 $25.8M
21 Emerald Advisers, LLC 0.69% 1,839,566 $21.9M
22 Silverarc Capital Management, LLC 0.62% 511,127 $6.1M
23 Siren, L.L.C. 0.59% 1,786,867 $21.3M
24 Orbimed Advisors LLC 0.58% 2,454,400 $29.3M
25 Opaleye Management Inc. 0.54% 345,100 $4.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Trevi Therapeutics Inc (TRVI)

What does the Smart Money Trend signal show for TRVI?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added TRVI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TRVI?

Slight buying edge — 55% buying: Last quarter: 108 funds bought or added vs 90 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for TRVI holders?

Strong quality — 23% AUM from major funds: 41 of 194 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TRVI?

Mixed — 30% long-term, 36% new: Of the 196 current holders: 59 (30%) held >2 years, 66 held 1–2 years, and 71 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Trevi Therapeutics Inc (TRVI) following the 2026 Q1 hedge fund 13F filings?

As of today, TRVI has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), TRVI has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →